Literature DB >> 1990009

The effects of different cysteine for glycine substitutions within alpha 2(I) chains. Evidence of distinct structural domains within the type I collagen triple helix.

R J Wenstrup1, A W Shrago-Howe, L W Lever, C L Phillips, P H Byers, D H Cohn.   

Abstract

Affected individuals from two apparently distinct, mild osteogenesis imperfecta families were heterozygous for a G to T transition in the COL1A2 gene that resulted in cysteine for glycine substitutions at position 646 in the alpha 2(I) chain of type I collagen. A child with a moderately severe form of osteogenesis imperfecta was heterozygous for a G to T transition that resulted in a substitution of cysteine for glycine at position 259 in the COL1A2 gene. Type I collagen molecules containing an alpha 2(I) chain with cysteine at position 259 denaturated at a lower temperature than molecules containing an alpha 2(I) chain with cysteine at position 646. In contrast to cysteine for glycine substitutions in the alpha 1(I) chain, the severity of the osteogenesis imperfecta phenotype is not directly proportional to the distance of the mutation from the amino-terminal end of the triple helix. These findings could be explained if the type I collagen triple helix contains discontinuous domains that differ in their contributions to maintaining helix stability.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1990009

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Three unrelated individuals with perinatally lethal osteogenesis imperfecta resulting from identical Gly502Ser substitutions in the alpha 2-chain of type I collagen.

Authors:  N J Rose; K Mackay; A De Paepe; B Steinmann; H H Punnett; R Dalgleish
Journal:  Hum Genet       Date:  1994-11       Impact factor: 4.132

2.  Substitution of glycine-661 by serine in the alpha1(I) and alpha2(I) chains of type I collagen results in different clinical and biochemical phenotypes.

Authors:  L Nuytinck; R Dalgleish; L Spotila; J P Renard; N Van Regemorter; A De Paepe
Journal:  Hum Genet       Date:  1996-03       Impact factor: 4.132

3.  Destabilization of osteogenesis imperfecta collagen-like model peptides correlates with the identity of the residue replacing glycine.

Authors:  K Beck; V C Chan; N Shenoy; A Kirkpatrick; J A Ramshaw; B Brodsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

4.  Osteogenesis imperfecta type III: mutations in the type I collagen structural genes, COL1A1 and COL1A2, are not necessarily responsible.

Authors:  G A Wallis; B Sykes; P H Byers; C G Mathew; D Viljoen; P Beighton
Journal:  J Med Genet       Date:  1993-06       Impact factor: 6.318

5.  Defective splicing of mRNA from one COL1A1 allele of type I collagen in nondeforming (type I) osteogenesis imperfecta.

Authors:  M L Stover; D Primorac; S C Liu; M B McKinstry; D W Rowe
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

6.  A single amino acid deletion in the alpha 2(I) chain of type I collagen produces osteogenesis imperfecta type III.

Authors:  K Molyneux; B J Starman; P H Byers; R Dalgleish
Journal:  Hum Genet       Date:  1993-02       Impact factor: 4.132

7.  A Gly238Ser substitution in the alpha 2 chain of type I collagen results in osteogenesis imperfecta type III.

Authors:  N J Rose; K Mackay; P H Byers; R Dalgleish
Journal:  Hum Genet       Date:  1995-02       Impact factor: 4.132

8.  Determination of a new collagen type I alpha 2 gene point mutation which causes a Gly640 Cys substitution in osteogenesis imperfecta and prenatal diagnosis by DNA hybridisation.

Authors:  M Gomez-Lira; A Sangalli; P F Pignatti; M C Digilio; A Giannotti; E Carnevale; M Mottes
Journal:  J Med Genet       Date:  1994-12       Impact factor: 6.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.